Tom Marsilje, a relentless advocate for cancer patients, dies at 45

Tom Marsilje was eternally optimistic and willing to give of his time to help his fellow cancer patients find clinical trials and experimental therapies.

When Tom Marsilje launched a website in May to help people with late-stage colorectal cancer find possible treatments through clinical trials, he pointed out the irony: “The ultimate CRC clinical trial advocate is unlikely to ever do a clinical trial,” he said.

He was right.

Marsilje, a Novartis scientist who helped develop a cutting-edge lung cancer treatment — and who, after his own colon cancer diagnosis, became a fierce advocate for his fellow patients — died Tuesday afternoon at a hospital in San Diego. He was 45.

The cancer support community was reeling in the wake of the

You're reading a preview, sign up to read more.

More from STAT

STAT4 min read
How The Drug Industry Keeps Winning In Washington
D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox. What if I told you the Sen. Thom Tillis campaign account was graced with nearly $20,000 in personal donations f
STAT5 min read
In A Small Study, A Cancer Vaccine Assist Beats Immunotherapy Drugs Alone
The largest study to date of a "cancer vaccine" found that combining it with an immunotherapy drug kept patients’ tumors in check longer, on average, than the drug alone.
STAT4 min readScience
HIV’s Genetic Code, Extracted From A Nub Of Tissue, Adds To Evidence Of Virus’ Emergence In Humans A Century Ago
In a nub of issue from the 1960s, scientists have found more clues of HIV’s emergence in humans.